Cymab ApS

Past relations

Ultimate beneficial owners (UBOs): Johan Henrik Faber
2019-06-01 – 54.81% ownership (2019-06-01 – ) 54.81% voting rights (2019-06-01 – )

Kurt Flemming Holmsted
2018-09-10 – 2019-06-01 46.8% ownership (2018-09-10 – 2019-06-01 ) 53.04% voting rights (2018-09-10 – 2019-06-01 )
Legal owners: Ebumab Holding ApS 100% ownership (2018-09-10 – ) 100% voting rights (2018-09-10 – )
Directors: Anne Reker Cordt
2024-06-24 –

Johan Henrik Faber
2023-04-17 –

Stine Louise Reedtz Kjellev
2023-04-17 – 2024-05-31

Hans Heugh Wandall
2021-05-21 – 2023-04-17

Johan Henrik Faber
2019-06-01 – 2023-04-16

Kurt Flemming Holmsted
2018-09-10 – 2019-06-01
Board members: Søren Erik Bjørn
2020-06-22 –

Mads Nikolaj Behrndt-Eriksen
2023-04-17 –

Anne Reker Cordt
2024-06-24 –

Johan Henrik Faber
2019-06-01 –

Thomas Dal Stenfeldt Batchelor
2021-05-21 – 2023-04-16

Hans Heugh Wandall
2020-06-22 – 2021-05-20

Thomas Dal Stenfeldt Batchelor
2019-06-01 – 2021-05-20

Kim Stengaard Holmsted
2018-09-10 – 2020-06-22

Hans Heugh Wandall
2018-09-10 – 2020-06-21

Kurt Flemming Holmsted
2018-09-10 – 2019-06-01

Cymab ApS has 4.00 full time equivalents (FTEs) and 4.00 employees as of 1 May, 2025.